BioCentury
ARTICLE | Clinical News

Xoma sinks on Phase III Behcet's data

July 23, 2015 1:19 AM UTC

Xoma Corp. (NASDAQ:XOMA) lost $3.39 (77%) to $1 after gevokizumab missed the primary endpoint in the Phase III EYEGUARD-B trial to treat Behcet's uveitis. The humanized IgG2 mAb against IL-1 beta failed to show a significant difference vs. placebo in time to first ocular exacerbation in the 83-patient study, which was conducted by Xoma's partner Servier (Neuilly-sure-Seine, France).

CEO John Varian said on a conference call that there was a greater than expected response in the placebo arm. ...